[1]陈新富 刘 宁 刘加夫.CK19在非小细胞肺癌淋巴结微转移中的检测价值(附90例分析)[J].福建医药杂志,2020,42(04):6-9.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(04):6-9.
点击复制

CK19在非小细胞肺癌淋巴结微转移中的检测价值(附90例分析)()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期数:
2020年04期
页码:
6-9
栏目:
临床研究
出版日期:
2020-08-20

文章信息/Info

Title:
Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases
文章编号:
1002-2600(2020)04-0006-04
作者:
陈新富 刘 宁 刘加夫1
福建省福州肺科医院胸外科(福州 350000)
Author(s):
CHEN Xinfu; LIU Ning; LIU Jiafu.
Department of Thoracic Surgery,Fuzhou Pulmonary Hospital of Fujian,Fuzhou,Fujian 350000,China
关键词:
非小细胞肺癌;  细胞角蛋白CK19;  淋巴结微转移;  淋巴结清扫术
Keywords:
non-small cell lung cancer;  cytokeratin CK19;  lymph node micrometastasis;  lymph node dissection
分类号:
R734.2
文献标志码:
B
摘要:
目的 分析pT1a～bN0M0 Ia1～2期非小细胞肺癌(NSCLC)患者术后淋巴结微转移情况、危险因素,以及淋巴结清扫术的方式。方法 应用免疫组化法检测90例经手术治疗的孤立单发直径≤2 cm的NSCLC患者CK19表达水平,以评估淋巴结微转移情况,并结合临床资料进行分析。结果 90例患者术后常规HE染色阴性淋巴结6例(6.6%)检出CK19阳性表达。微乳头或实性为主的病理类型、CEA水平≥5 ng/mL的患者,术后淋巴结CK19表达显著(P<0.05)。其中微乳头或实性为主的病理类型是发生淋巴结微转移的危险因素。纯磨玻璃结节术后淋巴结未发现微转移灶; 部分实性磨玻璃结节术后检出2例淋巴结微转移。结论 Ia期NSCLC患者可发生淋巴结微转移,微乳头或实性为主的病理类型是发生淋巴结微转移的危险因素; CT影像表现为纯磨玻璃的肺癌结节术中可避免行系统性淋巴结清扫; 部分实性磨玻璃结节,若术中冰冻病理提示有微乳头或实性为主或术前CEA水平≥5 ng/mL应行系统性淋巴结清扫。
Abstract:
Objective To analyze lymph node micrometastasis in the patients with non-small cell lung cancer(NSCLC)(pT1a-bN0M0 Ia1-2 stage,IASLC eighth edition of the TNM classification for lung cancer)after surgery,explore the risk factors of lymph node micrometastasis, and further analyze the choice of surgical procedures for stage Ia1-2 NSCLC lymph node dissection.Methods A total of 569 lymph nodes from 90 surgically treated isolated pulmonary nodules(diameter≤2 cm)were selected, the expression of CK19 was detected by immunohistochemistry and analyzed together with the clinical data.Results CK19 expression was detected in 6 cases(6.6%)of 90 patients with conventional H&E-staining negative lymph nodes after surgery.In patients with micropapillary or solid pathology type and CEA level ≥5 ng/mL, the expression of CK19 in lymph nodes was statistically different(P<0.05).Among them, micropapillary or solid pathology was a risk factor for lymph node micrometastasis.No micrometastasis were found in lymph nodes after pure Ground-Glass Opacity(pGGO)surgery; two cases of lymph node micrometastasis were detected after Part-solid GGO surgery.Conclusion Lymph node micrometastasis can occur in patients with stage Ia1-2 NSCLC.Micropapillary or solid pathology is a risk factor for lymph node micrometastasis.CT images show pure ground glass lung cancer nodules,which can be avoided during surgery.For some solid ground glass nodules, if intraoperative frozen pathology indicates micropapillary or solid components or preoperative CEA level ≥ 5 ng/mL,systemic lymph node dissection should be performed.

参考文献/References:

[1] Detterbeck F C,Franklin W A,Nicholson A G,et al.The IASLC lung cancer staging project:background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer[J].J Thorac Oncol,2016,11(5):651-665.
[2] 郝颖,付秀华,王丽红,等.检测非小细胞肺癌患者淋巴结中CK19、LunX、KS1/4的表达对诊断微转移的意义[J].国际呼吸杂志,2016,36(6):136-139.
[3] Buccheri G,Torchio P,Ferrigno D.Clinical equivalence of two cytokeratin markers in non-small cell lung cancer:A study of tissue polypeptide antigen and cytokeratin 19 fragments [J].Chest,2003,124(2):622-626.
[4] Suzuki K,Koike T,Asakawa T,et al.A prospective radio-logical study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer(Japan Clinical Oncology Group 0201)[J].J Thorac Oncol,2011,6(4):751-756.
[5] Fukui T,Katayama T,Ito S,et al.Clinicopathological fea-tures of small-sized non-small cell lung cancer with mediastinal lymph node metastasis [J].Lung Cancer,2009,66(3):309-313.
[6] Haro A,Yano T,Kohno M,et al.Ground-glass opacity lesions on computed tomography postoperative surveillance for primary non-small lung cancer[J].Lung Cancer,2012,76(1):56-60.
[7] 樊兴海,许秀春,叶波,等.临床T1期肺腺癌淋巴结转移危险因素分析[J]. 中华胸心血管外科杂志,2019,35(7):420-423.
[8] Dai C Y,Xie H K,Kadeer X,et al.Relationship of lymph node micormetastasis and micropapillary component and their joint Influence on prognosis of patients with stage I lung adenocarcinoma [J].Am J Surg Pathol,2017,41(9):1212-1220.

相似文献/References:

[1]林清华　吴联平　刘加夫　陈友轩　 齐春能　林玉琼　黄小红　郑　静.晚期非小细胞肺癌患者胸水液基细胞学蜡块中新抗体D5F3检测的临床价值[J].福建医药杂志,2019,41(01):3.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(04):3.
[2]林 潇 陈愉生 李鸿茹.查尔森合并症指数及简化合并症评分对晚期非小细胞肺癌预后的影响[J].福建医药杂志,2020,42(05):23.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(04):23.
[3]李荣宾,黄延延,林贤宾,等.IGF1/RPI3K/Akt通路及其调控对非小细胞肺癌血管生成拟态形成影响的研究[J].福建医药杂志,2023,45(03):112.
[4]黄阳,陈静波,林贵山.动态监测循环肿瘤细胞对寡转移非小细胞肺癌联合治疗预后的价值[J].福建医药杂志,2023,45(05):8.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(04):8.
[5]钟颖,邹立,陈声池.EGFR T790M突变丰度对阿美替尼治疗晚期非小细胞肺癌疗效的影响[J].福建医药杂志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(04):17.[doi:10.20148/j.fmj.2024.01.005]

备注/Memo

备注/Memo:
基金项目:福州市科技计划项目(2015-S-142-8)
更新日期/Last Update: 2020-08-20